EE673 Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients With Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results From the Final Analysis of Trial
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.938
https://www.valueinhealthjournal.com/article/S1098-3015(23)04068-8/fulltext
Section Title :
Section Order :
10429
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04068-8&doi=10.1016/j.jval.2023.09.938